Chosa Oncology

What Chosa Oncology does

CHOSA Oncology AB is a Swedish-domiciled precision oncology company (Org.no. 559037-2271) developing Platin-DRP®, a 205-gene biomarker signature test designed to predict which solid-tumor patients are most likely to benefit from platinum-based chemotherapy (cisplatin or carboplatin). The test analyzes gene expression from a routine biopsy and generates a score estimating platinum sensitivity, with validation derived from the Phase III SPLENDOUR trial (ETOP/EORTC) in 82 advanced NSCLC patients showing statistically significant PFS (HR 0.697, p=0.029) and OS (HR 0.602, p=0.011) advantages for high-scoring patients, and median OS of 16.9 months versus 5.5 months for low scorers. The company has additionally validated the assay on the NanoString platform and presented breast cancer combination data with AIDA at ASCO 2026 showing up to 78% pathological complete response rates.

The company is headquartered at Ole Maaløes Vej 3 in Copenhagen, with a Swedish registered office in Malmö (c/o ECIT Services) and a 2026-established US presence in Boston/Cambridge (1 Broadway, MA 02142). It is publicly listed (Frankfurt: W5L) but operates with only 1-10 employees, reflecting a virtual model that relies on an externalized ecosystem: ETOP and EORTC for clinical trial infrastructure, NanoString for platform execution, AIDA for breast cancer co-development, and seven named KOLs across lung, breast, bladder, and endometrial cancer for scientific credibility. Founder and CEO is Peter Buhl Jensen.

Commercially, CHOSA is pre-revenue with no disclosed paying customers or pricing; its stated revenue model is biomarker test sales and licensing to healthcare systems, hospitals, clinical laboratories, and pharmaceutical partners. Go-to-market focuses on evidence-based selling through scientific conferences (ESMO, ASCO, European Lung Cancer Congress), webinars, investor relations communications, and direct healthcare system engagement. Capital formation has been via a Rights Issue in 2025 and an approximately $354,624 raise in June 2025, supporting the move into US commercialization of Platin-DRP.

Name

Chosa Oncology

Legal name

CHOSA Oncology AB

Website

https://chosa.bio

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

CHOSA Oncology is a Swedish-Domiciled precision oncology company developing Platin-DRP®, a 205-gene biomarker test that predicts which solid-tumor patients will benefit from cisplatin or carboplatin chemotherapy, serving oncologists, hospitals, and pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Precision Oncology Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Proteomics & Biomarker Analytical Testing (HLAGADAG)

akta.pro secondary industry

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Precision oncology diagnostics
• Biomarker test development
• Platinum chemotherapy selection
• Gene expression analysis
• Cancer treatment stratification

Headquarters

HQ city

Lund

HQ country

Sweden

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Biomarker Test Sales/Licensing: Revenue generated from sales or licensing of the Platin-DRP® biomarker test to healthcare systems, hospitals, and clinical laboratories. The test is used to guide platinum treatment decisions in oncology.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

CHOSA Oncology offers the Platin-DRP® biomarker test, a 205-gene gene expression signature analyzed from routine tumor biopsies that produces a score estimating a patient's likelihood of benefiting from platinum-based chemotherapy (cisplatin or carboplatin). The test is designed to guide oncology treatment decisions and is compatible with the NanoString clinical laboratory platform. Revenue is generated through sales or licensing of the test to healthcare systems, hospitals, and clinical laboratories.

Product overview

CHOSA Oncology offers a single core product: Platin-DRP®, a precision oncology biomarker test designed to predict patient response to platinum-based chemotherapy. The test analyzes a 205-gene expression signature from routine biopsies to generate scores indicating which patients are most likely to benefit from cisplatin or carboplatin treatment. The product is primarily focused on lung cancer (NSCLC) with validation studies in breast cancer, and aims to improve response rates while reducing unnecessary toxicity exposure.

Differentiator

Problem solved

Functional benefit

Brands

• Platin-DRP®: A biomarker test designed to predict which patients are most likely to benefit from cisplatin or carboplatin treatment. The 205-gene biomarker signature generates a score estimating a patient's likelihood of benefiting from platinum-based therapy.

Products and services

• Platin-DRP® A 205-gene biomarker signature test that analyzes gene expression from routine tumor biopsies to generate a score estimating a patient's likelihood of benefiting from platinum-based chemotherapy (cisplatin or carboplatin). Designed for oncologists, hospitals, cancer treatment centers, and pharmaceutical partners developing platinum-based oncology regimens.

Quantifiable outcome

• HR 0.697 (p=0.029) improvement in progression-free survival for high Platin-DRP® scores vs low scores
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• AIDAcoreStrategic or Co-development Partner · 1 January 2026CHOSA and AIDA collaborated to present data at ASCO 2026 showing up to 78% pathological complete response (pCR) rate in breast cancer using combined, integrated, taxane and platinum biomarkers. This partnership combines biomarker expertise to advance precision oncology in breast cancer treatment.
• ETOP (European Thoracic Oncology Platform)coreStrategic or Co-development Partner · 1 January 2026ETOP collaborated with EORTC on the Phase III SPLENDOUR trial, from which CHOSA's Platin-DRP® biomarker data was derived through translational analysis. This partnership provided the clinical evidence base for the biomarker validation.
• EORTC (European Organisation for Research and Treatment of Cancer)coreStrategic or Co-development PartnerEORTC partnered with ETOP on the Phase III SPLENDOUR trial in advanced non-small cell lung cancer, providing the clinical trial infrastructure and patient population for Platin-DRP® validation.
• NanoString TechnologiescoreTechnology or IntegrationNanoString platform has been validated for running Platin-DRP® tests, demonstrating significant overall survival prediction in Phase III lung cancer studies. This integration enables the test to run on standardized clinical laboratory equipment.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Natera: Natera commercializes Signatera (MRD) and other oncology molecular tests for treatment monitoring and recurrence detection. Comparable as a precision oncology molecular diagnostics company monetizing biomarker tests through clinical channels.
• Foundation Medicine: Foundation Medicine offers comprehensive genomic profiling tests (FoundationOne CDx) widely used to guide oncology treatment selection. A direct peer in molecular tumor profiling, with substantially greater scale and commercial reach.
• Veracyte: Veracyte develops and commercializes genomic tests that resolve diagnostic ambiguity in oncology (e.g., Afirma, Percepta, Decipher). Directly comparable as a molecular diagnostics company selling biomarker tests into oncology clinical workflows.
• NeoGenomics: NeoGenomics provides oncology-focused clinical laboratory and molecular testing services used to guide treatment decisions. Directly comparable as a clinical lab and molecular diagnostics provider in oncology.
• Caris Life Sciences: Caris offers MI Profile and other molecular profiling assays used to inform oncology therapy selection. Directly comparable as a precision oncology profiling company monetizing biomarker-based decision support.
• Exact Sciences: Exact Sciences commercializes Oncotype DX and other genomic tests that guide oncology treatment decisions. Directly comparable as a molecular diagnostic company with established oncology test sales channels.
• Guardant Health: Guardant Health offers liquid biopsy-based oncology tests (Guardant360, Guardant Reveal) that inform treatment selection. Comparable as a precision oncology molecular diagnostics company, though focused on liquid biopsy rather than tissue gene-expression biomarkers.
• Personalis: Personalis provides tumor genomic profiling (NeXT Personal) used for ultra-sensitive cancer detection and treatment monitoring. Directly comparable as a smaller oncology molecular profiling peer focused on biomarker-driven decision support.
• Myriad Genetics: Myriad sells predictive genetic/molecular tests (BRACAnalysis, Prolaris, myChoice) that guide oncology treatment decisions. Directly comparable as a precision oncology diagnostic company monetizing tests through clinical laboratories and licensing.

Emerging players

• Strata Oncology: Strata Oncology develops tumor profiling and precision oncology enrollment programs for biomarker-driven therapy selection. An emerging peer with similar biomarker-guided treatment selection focus, though smaller and at an earlier commercial stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/chosa-oncology

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chosa Oncology